Cytomodulating peptide for inhibiting lymphocyte activity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6162434
SERIAL NO

08433613

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel oligopeptides comprising a sequence associated with HLA-B .alpha..sub.1 domain, but comprising a tyrosine-tyrosine-tryptophan triad are provided for use in inhibiting cytotoxic activity of CTLs and natural killer cells. By combining the subject compositions with mixtures of cells comprising the cytotoxic cells and cells which would otherwise activate the cytotoxic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a wide variety of other groups or compounds for varying the activity of the subject compositions. The subject compositions may be administered by any convenient means to a host to inhibit CTL and NK attack on tissue, particularly involved with xenogeneic or allogeneic transplants.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANGSTAT MEDICAL CORPORATION6300 DUMBARTON CIRCLE FREMONT CA USA 94555

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Buelow, Roland Palo Alto, CA 53 786

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation